DANONE (BSN.DE) Stock Fundamental Analysis
FRA:BSN - Deutsche Boerse Ag - FR0000120644 - Common Stock - Currency: EUR
Overall BSN gets a fundamental rating of 4 out of 10. We evaluated BSN against 58 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are concerns on its financial health. BSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
In the past year BSN had a positive cash flow from operations.
Each year in the past 5 years BSN has been profitable.
In the past 5 years BSN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BSN (4.46%) is better than 60.34% of its industry peers.
With a decent Return On Equity value of 11.34%, BSN is doing good in the industry, outperforming 63.79% of the companies in the same industry.
BSN's Return On Invested Capital of 6.58% is fine compared to the rest of the industry. BSN outperforms 62.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 7.19%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROIC | 6.58% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN's Profit Margin of 7.37% is fine compared to the rest of the industry. BSN outperforms 67.24% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
BSN's Operating Margin of 13.00% is fine compared to the rest of the industry. BSN outperforms 77.59% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
BSN has a better Gross Margin (49.70%) than 75.86% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BSN has been increased compared to 1 year ago.
Compared to 5 years ago, BSN has less shares outstanding
BSN has a better debt/assets ratio than last year.
2.2 Solvency
BSN has an Altman-Z score of 2.49. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
BSN has a Altman-Z score of 2.49. This is comparable to the rest of the industry: BSN outperforms 58.62% of its industry peers.
BSN has a debt to FCF ratio of 4.89. This is a neutral value as BSN would need 4.89 years to pay back of all of its debts.
The Debt to FCF ratio of BSN (4.89) is better than 72.41% of its industry peers.
A Debt/Equity ratio of 0.66 indicates that BSN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.66, BSN perfoms like the industry average, outperforming 43.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Altman-Z | 2.49 |
ROIC/WACC1.02
WACC6.44%
2.3 Liquidity
A Current Ratio of 0.93 indicates that BSN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.93, BSN is doing worse than 75.86% of the companies in the same industry.
BSN has a Quick Ratio of 0.93. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.77, BSN is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.54%.
Measured over the past years, BSN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.17% on average per year.
The Revenue has decreased by -0.88% in the past year.
BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.60% yearly.
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%2.81%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
3.2 Future
Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 6.38% on average per year.
The Revenue is expected to grow by 3.05% on average over the next years.
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y6.38%
Revenue Next Year2.6%
Revenue Next 2Y3.09%
Revenue Next 3Y3.32%
Revenue Next 5Y3.05%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.26 indicates a rather expensive valuation of BSN.
Compared to the rest of the industry, the Price/Earnings ratio of BSN is on the same level as its industry peers.
When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (28.22), we can say BSN is valued slightly cheaper.
The Price/Forward Earnings ratio is 19.69, which indicates a rather expensive current valuation of BSN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BSN is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.86, BSN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.69 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.04 | ||
| EV/EBITDA | 11.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.67
PEG (5Y)N/A
EPS Next 2Y7.64%
EPS Next 3Y7.59%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.83%, BSN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.11, BSN pays a bit more dividend than its industry peers.
BSN's Dividend Yield is comparable with the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
66.80% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP66.8%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
FRA:BSN (5/2/2025, 7:00:00 PM)
77.16
+1.24 (+1.63%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners54.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap52.43B
Analysts71.25
Price Target73.65 (-4.55%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP66.8%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.48%
PT rev (3m)6.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.09%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.51%
Revenue NY rev (3m)-0.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.69 | ||
| P/S | 1.92 | ||
| P/FCF | 18.04 | ||
| P/OCF | 13.69 | ||
| P/B | 2.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.24 |
EPS(TTM)3.63
EY4.7%
EPS(NY)3.92
Fwd EY5.08%
FCF(TTM)4.28
FCFY5.54%
OCF(TTM)5.64
OCFY7.3%
SpS40.29
BVpS26.18
TBVpS-9.15
PEG (NY)2.67
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROCE | 11.27% | ||
| ROIC | 6.58% | ||
| ROICexc | 8.06% | ||
| ROICexgc | 68% | ||
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% | ||
| FCFM | 10.62% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Debt/EBITDA | 2.49 | ||
| Cap/Depr | 79.02% | ||
| Cap/Sales | 3.37% | ||
| Interest Coverage | 20.69 | ||
| Cash Conversion | 81.04% | ||
| Profit Quality | 144.05% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 2.49 |
F-Score7
WACC6.44%
ROIC/WACC1.02
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%2.81%
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y6.38%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
Revenue Next Year2.6%
Revenue Next 2Y3.09%
Revenue Next 3Y3.32%
Revenue Next 5Y3.05%
EBIT growth 1Y2.24%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year38.47%
EBIT Next 3Y15.23%
EBIT Next 5Y10.44%
FCF growth 1Y11.98%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y11.24%
OCF growth 3Y3.31%
OCF growth 5Y2.15%